| Recruiting | A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participan NSCLC, Adjuvant Treatment | Phase 3 | 2025-05-28 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Table Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 | 2025-03-04 |
| Recruiting | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861 EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | 2024-11-19 |
| Recruiting | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With NSCLC Patients With Brain Metastasis | Phase 3 | 2024-09-26 |
| Recruiting | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 3 | 2024-08-07 |
| Completed | A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects Healthy Subjects | Phase 1 | 2023-11-25 |
| Recruiting | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tum KRAS P.G12C, Pancreatic Cancer, Solid Tumor | Phase 2 | 2023-10-27 |
| Completed | Mass Balance Study of [14C]JAB-21822 Mass Balance Study in Healthy Subjects | Phase 1 | 2023-07-08 |
| Completed | A Food Effect Study of JAB-21822 in Healthy Subjects Food Effect in Healthy Participants | Phase 1 | 2023-05-12 |
| Active Not Recruiting | Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 I NSCLC | Phase 2 | 2022-09-27 |
| Recruiting | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2022-08-17 |
| Recruiting | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutat KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 / Phase 2 | 2022-04-14 |
| Active Not Recruiting | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mu Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer | Phase 1 / Phase 2 | 2022-02-17 |
| Withdrawn | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation NSCLC | Phase 1 | 2021-10-01 |
| Active Not Recruiting | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China NSCLC, Solid Tumor | Phase 1 / Phase 2 | 2021-07-26 |
| Recruiting | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Re Non-small Cell Lung Carcinoma | Phase 3 | 2021-06-07 |
| Completed | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Solid Tumor, NSCLC | Phase 1 / Phase 2 | 2021-03-23 |
| Active Not Recruiting | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation NSCLC | Phase 1 | 2020-08-10 |
| Completed | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma | Phase 1 | 2020-07-14 |
| Active Not Recruiting | Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cance Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | Phase 3 | 2019-05-30 |
| Completed | Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Vo Healthy Male Volunteers | Phase 1 | 2019-04-08 |
| Completed | Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Ma Healthy Male Volunteers | Phase 1 | 2019-02-19 |
| Terminated | Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T Advanced NSCLC Patients With T790M | Phase 2 | 2018-04-30 |
| Terminated | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Advanced NSCLC | N/A | 2017-06-01 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung NSCLC | Phase 1 | 2016-12-30 |